ArticleFrontiers in psychiatry2025
Reduced risk of severe COVID-19 with lithium use: a large-scale comparison with valproate users and other COVID-19 patients.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lithium, a commonly used mood stabilizer with immunomodulatory and antiviral properties, has been hypothesized to lessen the severity of COVID-19, but population-level evidence remains limited. Methods: In this retrospective cohort study, we examined electronic health records from over 1.49 million adults with confirmed COVID-19 in Israel between March 2020 and November 2021. Individuals were categorized based on sustained use of lithium (n=857), valproate (n=5,302), or no exposure to either medication. Severe COVID-19 was defined as hospitalization, respiratory support, extracorporeal membrane oxygenation, or death. To account for baseline differences, we applied inverse probability weighting and logistic regression with correction for rare events. Results: Lithium use was associated with significantly lower odds of severe COVID-19, even though users were older and had more medical comorbidities. In contrast, valproate use was linked to increased risk. Conclusion: These findings suggest that lithium may provide a protective effect against severe COVID-19 outcomes, independent of underlying vulnerability, and support further investigation into the broader health implications of psychotropic medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.